Infliximab for the treatment of immune checkpoint inhibitor-associated acute kidney injury
Nephrology Dialysis Transplantation · 30.10.2026 · 41 (11) · 2091-2094
DOI: 10.1093/ndt/gfag200 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 29.08.2026. Verfasst von Rishi R Patel und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA. Die Arbeit nennt 14 Literaturangaben. Gefördert von: University Hospitals Cleveland Medical Center, IRB.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Internal Medicine, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.
- Department of Hematology/Oncology, University Hospitals Seidman Cancer Center, Cleveland, Ohio, USA.
- Division of Nephrology & Hypertension, Department of Medicine, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.
Förderung
- University Hospitals Cleveland Medical Center
- IRB
Zitieren
APA
Patel, R. R., Myers, K. E., Mirsky, M. M., Sheng, I., & Rashidi, A. (2026). Infliximab for the treatment of immune checkpoint inhibitor-associated acute kidney injury. Nephrology Dialysis Transplantation, 41(11), 2091-2094. https://doi.org/10.1093/ndt/gfag200
Vancouver
Patel RR, Myers KE, Mirsky MM, Sheng I, Rashidi A. Infliximab for the treatment of immune checkpoint inhibitor-associated acute kidney injury. Nephrology Dialysis Transplantation. 2026;41(11):2091-2094. doi:10.1093/ndt/gfag200
BibTeX
@article{Patel2026,
author = {Patel, Rishi R and Myers, Katherine E and Mirsky, Matthew M and Sheng, Iris and Rashidi, Arash},
title = {Infliximab for the treatment of immune checkpoint inhibitor-associated acute kidney injury},
journal = {Nephrology Dialysis Transplantation},
year = {2026},
volume = {41},
number = {11},
pages = {2091--2094},
doi = {10.1093/ndt/gfag200}
}
EUVIMED